Tags

Type your tag names separated by a space and hit enter

Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b.
Sarcoidosis Vasc Diffuse Lung Dis. 2005 Oct; 22(3):204-9.SV

Abstract

BACKGROUND AND AIM

Interleukin-18 (IL-18) has been identified as an interferon-gamma (IFN-gamma) mediator, promoting a T helper 1 (Th1) response. Th1 response is characterized by increased expression of IFN-gamma, interleukin-12 (IL-12) and interleukin-18 (IL-18). The present study aims to evaluate the role of Th1 cytokines by monitoring changes in Induced Sputum (IS) samples, before and after treatment with IFN-gamma-1b in patients with IPF.

PATIENTS AND METHODS

Fifteen patients with histologically confirmed IPF/UIP (12 male, 3 female) of median age 65 yr were prospectively studied. Ten healthy subjects (5 female, 5 male) of median age 61 yr served as control group. Patients were assigned to receive IFN-gamma-1b 200 microg (15 patients) subcutaneously three times per week for 12 months. Induced sputum (IS) IL-12 and IL-18 levels were measured before and after IFN-gamma-1b treatment in IPF patients as well as in healthy controls, using ELISA immunoassay.

RESULTS

The IL-18 levels were significantly higher in IPF samples before treatment than in healthy controls (57.05 +/- 6.9 pg/ml vs. 41.07 +/- 8.16 pg/ml, p < 0.05). A statistically significant decrease was detected in the IL-18 levels after IFN-gamma-1b treatment (57.05 +/- 6.9 vs. 42.8 +/- 5.1 pg/ml, p = 0.04). The IL-12 supernatant levels measured before and after IFN-gamma-1b treatment were not significantly different.

CONCLUSIONS

Our results may illustrate the potential role of IL-18 as an inflammatory molecule in the pathogenesis of IPF. Moreover, decrease of IL-18 levels in IPF patients, after 12 months of therapy could possibly be explained as IL-18 downregulation after IFN-gamma-1b treatment. Extended studies are needed to determine the precise role of IL-12 and IL-18 during IPF.

Authors+Show Affiliations

Interstitial Lung Disease Unit, Department of Thoracic Medicine, University General Hospital, Medical School, University of Crete, Heraklion.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16315783

Citation

Antoniou, Katerina M., et al. "Investigation of IL-18 and IL-12 in Induced Sputum of Patients With IPF Before and After Treatment With Interferon Gamma-1b." Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG, vol. 22, no. 3, 2005, pp. 204-9.
Antoniou KM, Tzortzaki EG, Alexandrakis MG, et al. Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(3):204-9.
Antoniou, K. M., Tzortzaki, E. G., Alexandrakis, M. G., Zervou, M., Tzanakis, N., Sfiridaki, K., Bouros, D. E., & Siafakas, N. M. (2005). Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG, 22(3), 204-9.
Antoniou KM, et al. Investigation of IL-18 and IL-12 in Induced Sputum of Patients With IPF Before and After Treatment With Interferon Gamma-1b. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(3):204-9. PubMed PMID: 16315783.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. AU - Antoniou,Katerina M, AU - Tzortzaki,Eleni G, AU - Alexandrakis,Michael G, AU - Zervou,Maria, AU - Tzanakis,Nikolaos, AU - Sfiridaki,Katerina, AU - Bouros,Demosthenes E, AU - Siafakas,Nikolaos M, PY - 2005/12/1/pubmed PY - 2006/1/27/medline PY - 2005/12/1/entrez SP - 204 EP - 9 JF - Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG JO - Sarcoidosis Vasc Diffuse Lung Dis VL - 22 IS - 3 N2 - BACKGROUND AND AIM: Interleukin-18 (IL-18) has been identified as an interferon-gamma (IFN-gamma) mediator, promoting a T helper 1 (Th1) response. Th1 response is characterized by increased expression of IFN-gamma, interleukin-12 (IL-12) and interleukin-18 (IL-18). The present study aims to evaluate the role of Th1 cytokines by monitoring changes in Induced Sputum (IS) samples, before and after treatment with IFN-gamma-1b in patients with IPF. PATIENTS AND METHODS: Fifteen patients with histologically confirmed IPF/UIP (12 male, 3 female) of median age 65 yr were prospectively studied. Ten healthy subjects (5 female, 5 male) of median age 61 yr served as control group. Patients were assigned to receive IFN-gamma-1b 200 microg (15 patients) subcutaneously three times per week for 12 months. Induced sputum (IS) IL-12 and IL-18 levels were measured before and after IFN-gamma-1b treatment in IPF patients as well as in healthy controls, using ELISA immunoassay. RESULTS: The IL-18 levels were significantly higher in IPF samples before treatment than in healthy controls (57.05 +/- 6.9 pg/ml vs. 41.07 +/- 8.16 pg/ml, p < 0.05). A statistically significant decrease was detected in the IL-18 levels after IFN-gamma-1b treatment (57.05 +/- 6.9 vs. 42.8 +/- 5.1 pg/ml, p = 0.04). The IL-12 supernatant levels measured before and after IFN-gamma-1b treatment were not significantly different. CONCLUSIONS: Our results may illustrate the potential role of IL-18 as an inflammatory molecule in the pathogenesis of IPF. Moreover, decrease of IL-18 levels in IPF patients, after 12 months of therapy could possibly be explained as IL-18 downregulation after IFN-gamma-1b treatment. Extended studies are needed to determine the precise role of IL-12 and IL-18 during IPF. SN - 1124-0490 UR - https://www.unboundmedicine.com/medline/citation/16315783/Investigation_of_IL_18_and_IL_12_in_induced_sputum_of_patients_with_IPF_before_and_after_treatment_with_interferon_gamma_1b_ L2 - https://medlineplus.gov/pulmonaryfibrosis.html DB - PRIME DP - Unbound Medicine ER -